MECOM and leukemia: To advance in vivo proof-of-concept investigations, initial steps could include isolating endogenously occurring MECOM::ETV6 fusion products from the primary leukemia patient cells, mapping the nucleotide sequences of the breakpoints, characterizing potential functional elements, and generating immortalized cell lines using the chimeric fusion genes.